biguanides has been researched along with Pressure Ulcer in 14 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Pressure Ulcer: An ulceration caused by prolonged pressure on the SKIN and TISSUES when one stays in one position for a long period of time, such as lying in bed. The bony areas of the body are the most frequently affected sites which become ischemic (ISCHEMIA) under sustained and constant pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study evaluated eradication of methicillin-resistant Staphylococcus aureus (MRSA) from pressure ulcers comparing swabs containing polyhexanide with a cellulose dressing + polyhexanide." | 9.16 | Eradication of methicillin-resistant Staphylococcus aureus in pressure ulcers comparing a polyhexanide-containing cellulose dressing with polyhexanide swabs in a prospective randomized study. ( Andriessen, A; Bruckner, M; Eberlein, T; Payrich, M; Schwarz, C; Wild, T, 2012) |
| " Our aim was to assess the clinical efficacy of a propylbetaine-polihexanide (PP) solution versus normal saline (NS) solution in WBP, assessing inflammatory signs and wound size reduction in patients with pressure ulcers (PUs) or vascular leg ulcers." | 5.22 | Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT. ( Bellingeri, A; Chiari, P; Falciani, F; Moscatelli, A; Peghetti, A; Russo, A; Tino, G; Traspedini, P, 2016) |
| "The study evaluated eradication of methicillin-resistant Staphylococcus aureus (MRSA) from pressure ulcers comparing swabs containing polyhexanide with a cellulose dressing + polyhexanide." | 5.16 | Eradication of methicillin-resistant Staphylococcus aureus in pressure ulcers comparing a polyhexanide-containing cellulose dressing with polyhexanide swabs in a prospective randomized study. ( Andriessen, A; Bruckner, M; Eberlein, T; Payrich, M; Schwarz, C; Wild, T, 2012) |
| "Wounds were evenly distributed with respect to etiology and both study groups had a median baseline wound size of 7 cm2." | 2.71 | Impact of antimicrobial gauze on bacterial colonies in wounds that require packing. ( Corbett, LQ; Milne, CT; Motta, GJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Monteiro Vasconcelos, F | 1 |
| Cabral Pereira da Costa, C | 1 |
| Peres, EM | 1 |
| Souza Leão, R | 1 |
| Ferraz Gomes, H | 1 |
| Silva Thiengo Andrade, PC | 1 |
| Silva Pires, A | 1 |
| Faria, C | 1 |
| Oliveira Motta, AP | 1 |
| Barreto Pires, BMF | 1 |
| Menack, MJ | 1 |
| Thibodeaux, KT | 1 |
| Trabanco, C | 1 |
| Sabolinski, ML | 1 |
| Sams-Dodd, J | 1 |
| Sams-Dodd, F | 1 |
| Atkin, L | 1 |
| Stephenson, J | 1 |
| Cooper, DM | 1 |
| Nie, AM | 1 |
| Lintzeris, D | 1 |
| Vernon, K | 1 |
| Percise, H | 1 |
| Strickland, A | 1 |
| Yarrow, K | 1 |
| White, A | 1 |
| Gurganus, M | 1 |
| Sherrod, S | 1 |
| Vergin, K | 1 |
| Johnson, L | 1 |
| Bellingeri, A | 1 |
| Falciani, F | 1 |
| Traspedini, P | 1 |
| Moscatelli, A | 1 |
| Russo, A | 1 |
| Tino, G | 1 |
| Chiari, P | 1 |
| Peghetti, A | 1 |
| Valenzuela, AR | 1 |
| Perucho, NS | 1 |
| Dissemond, J | 1 |
| Gerber, V | 1 |
| Kramer, A | 1 |
| Riepe, G | 1 |
| Strohal, R | 1 |
| Vasel-Biergans, A | 1 |
| Eberlein, T | 2 |
| Romanelli, M | 1 |
| Dini, V | 1 |
| Barbanera, S | 1 |
| Bertone, MS | 1 |
| Sibbald, RG | 1 |
| Coutts, P | 1 |
| Woo, KY | 1 |
| Wild, T | 1 |
| Bruckner, M | 1 |
| Payrich, M | 1 |
| Schwarz, C | 1 |
| Andriessen, A | 1 |
| Motta, GJ | 1 |
| Milne, CT | 1 |
| Corbett, LQ | 1 |
| Michel, D | 1 |
| Zäch, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel[NCT03369756] | 43 participants (Actual) | Interventional | 2018-02-20 | Terminated (stopped due to Terminated due to prolonged subject recruitment) | |||
| Kerlix AMD Gauze Study In A Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients[NCT00656708] | 108 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Body consists of Items #1 to #5. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Body Subscore change, Baseline / Week 1 to Week 2 | Body Subscore change, Baseline / Week 1 to Week 3 | Body Subscore change, Baseline / Week 1 to Week 4 | Body Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.76 | -0.93 | -1.19 | -1.17 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Everyday Life consists of Items #Items #11 to #16. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. Generally, the higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Everyday Life Subscore change, Baseline / Week 1 to Week 2 | Everyday Life Subscore change, Baseline / Week 1 to Week 3 | Everyday Life Subscore change, Baseline / Week 1 to Week 4 | Everyday Life Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.58 | -0.82 | -1.11 | -1.00 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Psyche consists of Items #Items #6 to #10. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Psyche Subscore change, Baseline / Week 1 to Week 2 | Psyche Subscore change, Baseline / Week 1 to Week 3 | Psyche Subscore change, Baseline / Week 1 to Week 4 | Psyche Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.77 | -1.04 | -1.24 | -1.26 |
Change in wound size from Baseline/Week 1 to Final/Week 5. The change in the size of a wound will be evaluated using a disposable ruler to directly measure the overall wound dimensions at each scheduled visit to the study site (Weeks 1 and 5). These measurements will be done before any cleaning of the wound and after cleaning the wound (debridement). (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | wound surface area (cm^2) (Mean) | |
|---|---|---|
| Pre-Debridement Wound Size Change (Baseline/Week 1 to Week 5 / End) | Post-Debridement Wound Size Change(Baseline/Week 1 to Final/Week 5) | |
| Prontosan Solution and Gel | -6.6 | -8.2 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice.~Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). A Total or Global score is the average of at least 13 completed questions, regardless of which questions were not completed. The average of each of the 3 subscales can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 / Baseline | Week 2 | Week 3 | Week 4 | Week 5 / End | |
| Prontosan Solution and Gel | 2.41 | 1.74 | 1.51 | 1.25 | 1.30 |
2 reviews available for biguanides and Pressure Ulcer
| Article | Year |
|---|---|
Wound bed preparation: a case series using polyhexanide and betaine solution and gel-a UK perspective.
Topics: Administration, Cutaneous; Betaine; Biguanides; Gels; Humans; Pressure Ulcer; State Medicine; Therap | 2020 |
Pressure Injury Prevention and Treatment in Critically Ill Children.
Topics: Age Factors; Biguanides; Child; Child Development; Critical Illness; Disinfectants; Humans; Hydrogel | 2020 |
7 trials available for biguanides and Pressure Ulcer
| Article | Year |
|---|---|
Microbiological identification and resistance profile of microorganisms in pressure injuries after the use of polyhexamethylene biguanide: a series of fourteen cases.
Topics: Anti-Bacterial Agents; Biguanides; Humans; Methicillin-Resistant Staphylococcus aureus; Pressure Ulc | 2022 |
Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT.
Topics: Aged; Aged, 80 and over; Bandages; Betaine; Biguanides; Chronic Disease; Female; Humans; Inflammatio | 2016 |
[The effectiveness of a 0.1% polyhexanide gel].
Topics: Administration, Topical; Biguanides; Debridement; Gels; Health Policy; Humans; Pressure Ulcer; Treat | 2008 |
Evaluation of the efficacy and tolerability of a solution containing propyl betaine and polihexanide for wound irrigation.
Topics: Aged; Anti-Infective Agents, Local; Betaine; Biguanides; Biofilms; Female; Humans; Hydrogen-Ion Conc | 2010 |
Reduction of bacterial burden and pain in chronic wounds using a new polyhexamethylene biguanide antimicrobial foam dressing-clinical trial results.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bandages; Biguanides; Canada; Chro | 2011 |
Eradication of methicillin-resistant Staphylococcus aureus in pressure ulcers comparing a polyhexanide-containing cellulose dressing with polyhexanide swabs in a prospective randomized study.
Topics: Adult; Aged; Bandages; Biguanides; Cellulose; Disease Progression; Female; Health Status Indicators; | 2012 |
Impact of antimicrobial gauze on bacterial colonies in wounds that require packing.
Topics: Aged; Aged, 80 and over; Bandages; Biguanides; Colony Count, Microbial; Diabetic Foot; Disinfectants | 2004 |
5 other studies available for biguanides and Pressure Ulcer
| Article | Year |
|---|---|
Effectiveness of type I collagen matrix plus polyhexamethylene biguanide antimicrobial for the treatment of pressure injuries.
Topics: Aged; Anti-Bacterial Agents; Biguanides; Collagen Type I; Female; Humans; Male; Pressure Ulcer; Pros | 2022 |
Micropore Particle Technology Promotes Wound Healing, Whereas Polyhexamethylene Biguanide Causes Tissue Degeneration: A Case Report.
Topics: Abscess; Aged; Anti-Infective Agents, Local; Biguanides; Biomedical Technology; Debridement; Exudate | 2020 |
Effect of a New Purified Collagen Matrix With Polyhexamethylene Biguanide on Recalcitrant Wounds of Various Etiologies: A Case Series.
Topics: Aged; Anti-Infective Agents, Local; Biguanides; Calciphylaxis; Chronic Disease; Collagen Type I; Dia | 2018 |
A practice-oriented recommendation for treatment of critically colonised and locally infected wounds using polihexanide.
Topics: Acute Disease; Bacterial Infections; Biguanides; Chronic Disease; Contraindications; Disinfectants; | 2010 |
Antiseptic efficacy of disinfecting solutions in suspension test in vitro against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli in pressure sore wounds after spinal cord injury.
Topics: Anti-Infective Agents, Local; Biguanides; Chamomile; Chlorhexidine; Escherichia coli; Escherichia co | 1997 |